Merrimack Pharmaceuticals, Inc. (MACK) Reaches $11.37 After 5.00% Up Move; Shorts at ORIX CORPORATION ORDINARY SHARES (ORXCF) Lowered By 3.73%

February 22, 2018 - By Louis Casey

ORIX CORPORATION ORDINARY SHARES (OTCMKTS:ORXCF) had a decrease of 3.73% in short interest. ORXCF’s SI was 1.40 million shares in February as released by FINRA. Its down 3.73% from 1.45M shares previously. With 1,400 avg volume, 996 days are for ORIX CORPORATION ORDINARY SHARES (OTCMKTS:ORXCF)’s short sellers to cover ORXCF’s short positions. The SI to ORIX CORPORATION ORDINARY SHARES’s float is 0.11%. It closed at $18 lastly. It is down 0.00% since February 22, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is a huge mover today! The stock increased 3.65% or $0.4 during the last trading session, reaching $11.37. About 68,007 shares traded. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) has declined 44.78% since February 22, 2017 and is downtrending. It has underperformed by 61.48% the S&P500.The move comes after 5 months positive chart setup for the $151.66 million company. It was reported on Feb, 22 by Barchart.com. We have $11.94 PT which if reached, will make NASDAQ:MACK worth $7.58M more.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company has market cap of $151.66 million. The company's therapeutic oncology candidates in clinical development include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer; and MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1. It has a 0.33 P/E ratio. The Company’s therapeutic oncology candidates also comprise MM-310 for treating solid tumors; and MM-151 that has completed a Phase I clinical trial for treating solid tumors.

Since September 11, 2017, it had 0 insider buys, and 2 sales for $422,765 activity. The insider Nielsen Ulrik B. sold $310,408.

Among 5 analysts covering Merrimack Pharmaceuticals (NASDAQ:MACK), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Merrimack Pharmaceuticals has $16 highest and $8 lowest target. $14.33’s average target is 26.03% above currents $11.37 stock price. Merrimack Pharmaceuticals had 10 analyst reports since August 12, 2015 according to SRatingsIntel. The company was maintained on Tuesday, August 11 by Brean Capital. As per Friday, May 27, the company rating was initiated by Robert W. Baird. BTIG Research initiated the stock with “Neutral” rating in Friday, August 19 report. Robert W. Baird maintained it with “Hold” rating and $15.0 target in Friday, October 13 report. The firm earned “Outperform” rating on Wednesday, August 12 by Mizuho. The rating was downgraded by JP Morgan to “Neutral” on Friday, October 7. On Tuesday, October 27 the stock rating was maintained by Oppenheimer with “Outperform”. Robert W. Baird maintained it with “Hold” rating and $15.0 target in Monday, September 11 report. Oppenheimer reinitiated Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) on Wednesday, August 12 with “Outperform” rating. The company was maintained on Wednesday, December 23 by Mizuho.

Analysts await Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) to report earnings on March, 7. They expect $-0.28 earnings per share, up 88.80% or $2.22 from last year’s $-2.5 per share. After $-0.40 actual earnings per share reported by Merrimack Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -30.00% EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>